The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab
Abstract
BACKGROUND: Bevacizumab (Avastin; rhuMab VEGF), a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), significantly prolongs survival when added to intravenous 5-fluorouracil-based chemotherapy in first-line metastatic colorectal cancer (CRC) treatment. Because antiangiogenic agents might inhibit wound healing, we assessed postoperative wound healing complications in two randomized trials of 5 mg/kg bevacizumab in CRC treatment. METHODS: We assessed the wound healing complications in patients who: (1) underwent cancer surgery 28-60 days before study treatment and (2) underwent major surgery during study treatment. Cases were reviewed for wound healing complications occurring < or = 60 days after surgery. RESULTS: With cancer surgery 28-60 days before study treatment, wound healing complications occurred in 3/230 (1.3%) bevacizumab-treated patients and 1/194 (0.5%) control patients. With major surgery during study treatment, 10/75 bevacizumab-treated patients (13%) and 1/29 control patients (3.4%) had wound healing complications. Bevacizumab-treated patients experienced complications with surgery < or = 30 and 31-60 days after the last dose. CONCLUSIONS: Bevacizumab administered in combination with 5-fluorouracil/leucovorin-based chemotherapy 28-60 days after primary cancer surgery caused no increased risk of wound healing complications compared with chemotherapy alone. While wound healing complications were increased in patients who had major surgery during bevacizumab therapy, the majority of bevacizumab-treated patients experienced no complications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Self-citationThe Biology of Vascular Endothelial Growth Factor
Ferrara, N., & Davis-Smyth, T. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.1.0287 · Cited by 4,330
(1947) · The American Statistician · doi:10.1080/00031305.1947.10501534 · Cited by 3,660
Collett, D. (1991) · Springer eBooks · doi:10.1007/978-1-4899-4475-7 · Cited by 1,936
Kabbinavar, F. F., Schulz, J., McCleod, M., Patel, T., Hamm, J. T., Hecht, J. R., Mass, R., Perrou, B., Nelson, B., & Novotny, W. F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.112 · Cited by 929
Self-citationFERRARA, N. (2002) · Seminars in Oncology · doi:10.1016/s0093-7754(02)70064-x · Cited by 623
Marijnen, C. A. M., Kapiteijn, E., van de Velde, C. J. �., Martijn, H., Steup, W. H., Wiggers, T., Kranenbarg, E. M., Leer, J. W. H., & the Cooperative Investigators of the Dutch Colorectal Cancer Group (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.3.817 · Cited by 599
Petrelli, N., Douglass, H. O., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., & Muggia, F. M. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.10.1419 · Cited by 556
Ferrara, N. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.37264 · Cited by 546
Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.120 · Cited by 223
Sauer, R., Fietkau, R., Wittekind, C., Rödel, C., Martus, P., Hohenberger, W., Tschmelitsch, J., Sabitzer, H., Karstens, J. ‐., Becker, H., et al. (2003) · Colorectal Disease · doi:10.1046/j.1463-1318.2003.00509.x · Cited by 219
Carlson, M. A. (1997) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70571-5 · Cited by 217
A Comparison of Approximate Interval Estimators for the Bernoulli Parameter
Leemis, L. M., & Trivedi, K. S. (1996) · The American Statistician · doi:10.1080/00031305.1996.10473544 · Cited by 217
Streit, M. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3272 · Cited by 208
The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing
Bloch, W., Huggel, K., Sasaki, T., Grose, R., Bugnon, P., Addicks, K., Timpl, R., & Werner, S. (2000) · The FASEB Journal · doi:10.1096/fj.00-0490fje · Cited by 171
Saltz, L. B., Kanowitz, J., Kemeny, N. E., Schaaf, L. J., Spriggs, D. R., Staton, B. A., Berkery, R., Steger, C., Eng, M., Dietz, A. B., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2959 · Cited by 145
Gislason, H., Grønbech, J. E., & Söreide, O. (1995) · PubMed · Cited by 142
The Angiogenesis Inhibitor, Endostatin, Does Not Affect Murine Cutaneous Wound Healing
Berger, A. C., Feldman, A. L., Gnant, M., Kruger, E. A., Sim, B. K. L., Hewitt, S. M., Figg, W. D., Alexander, H. R., & Libutti, S. K. (2000) · Journal of Surgical Research · doi:10.1006/jsre.2000.5890 · Cited by 108
Lockhart, A. C., Braun, R. D., Yu, D., et al. (2003) · PubMed · Cited by 90
Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin.
Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R. J., Neider, R. S., Sebree, L., & Friedl, A. (2001) · PubMed · Cited by 87
The Angiogenesis Inhibitor Vasostatin does not Impair Wound Healing at Tumor-Inhibiting Doses
Lange‐Asschenfeldt, B., Velasco, P., Streit, M., Hawighorst, T., Detmar, M. J., Pike, S. E., & Tosato, G. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01519.x · Cited by 63
van der Bilt, J. D. W., & Rinkes, I. H. M. B. (2004) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2004.01.003 · Cited by 48
Velde, E. A. T., Voest, E. E., van Gorp, J. M., Verheem, A., Hagendoorn, J., Gebbink, M. F. B. G., & Rinkes, I. H. M. B. (2002) · Annals of Surgical Oncology · doi:10.1007/bf02573070 · Cited by 36
Cited by
Factors affecting wound healing
Guo, S., & DiPietro, L. A. (2010) · Journal of Dental Research · doi:10.1177/0022034509359125 · Cited by 5,792
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H. T., Minsky, B., Nordlinger, B., & Starling, N. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60353-4 · Cited by 1,351
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
Metadata
- Authors
- Scappaticci, F. A., Fehrenbacher, L., Cartwright, T., Hainsworth, J. D., Heim, W., Berlin, J., Kabbinavar, F., Novotny, W., Sarkar, S., & Hurwitz, H.
- Venue
- Journal of Surgical Oncology
- Publisher
- Wiley
- Published
- 2005
- Volume
- 91
- Issue
- 3
- Pages
- 173-180
- ISSN
- 0022-4790 (ISSN-L)
- 1096-9098
- OpenAlex
- W2033597946
- Cited by
- 537
- References
- 23
- FWCI
- 19.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.